NASDAQ:QNCX Quince Therapeutics (QNCX) Stock Price, News & Analysis $34.04 +1.63 (+5.03%) Closing price 08/14/2026 04:00 PM EasternExtended Trading$33.60 -0.44 (-1.29%) As of 08/14/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrendsBuy This Stock About Quince Therapeutics Stock (NASDAQ:QNCX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Quince Therapeutics alerts:Sign Up Key Stats Today's Range$31.78▼$35.2050-Day Range$16.75▼$34.0452-Week Range$15.10▼$909.98Volume26,046 shsAverage Volume35,861 shsMarket Capitalization$34.62 millionP/E RatioN/ADividend YieldN/APrice Target$310.50Consensus RatingHold Company Overview Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California. Read More Quince Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks61st Percentile Overall ScoreQNCX MarketRank™: Quince Therapeutics scored higher than 61% of companies evaluated by MarketBeat, and ranked 368th out of 914 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingHold Consensus RatingQuince Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.27, and is based on 1 strong buy rating, 3 buy ratings, 5 hold ratings, and 2 sell ratings.Upside PotentialQuince Therapeutics has a consensus price target of $310.50, representing about 812.2% upside from its current price of $34.04.Amount of Analyst CoverageQuince Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Quince Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Quince Therapeutics are expected to decrease in the coming year, from ($2.72) to ($5.35) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Quince Therapeutics is -0.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Quince Therapeutics is -0.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted5.99% of the float of Quince Therapeutics has been sold short.Short Interest Ratio / Days to CoverQuince Therapeutics has a short interest ratio ("days to cover") of 1.52, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Quince Therapeutics has recently increased by 11.98%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldQuince Therapeutics does not currently pay a dividend.Dividend GrowthQuince Therapeutics does not have a long track record of dividend growth. News and Social Media4.5 / 5News Sentiment1.22 News SentimentQuince Therapeutics has a news sentiment score of 1.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.67 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Quince Therapeutics this week, compared to 2 articles on an average week.Search Interest3 people have searched for QNCX on MarketBeat in the last 30 days. MarketBeat Follows3 people have added Quince Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership0.6 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Quince Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders7.10% of the stock of Quince Therapeutics is held by insiders.Percentage Held by Institutions30.75% of the stock of Quince Therapeutics is held by institutions.Read more about Quince Therapeutics' insider trading history. Receive QNCX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Quince Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. QNCX Stock News HeadlinesQuince Therapeutics Reports Second Quarter 2026 Financial Results and Corporate UpdateAugust 14 at 8:00 AM | globenewswire.comQuince Therapeutics (QNCX) Projected to Announce Earnings on TuesdayAugust 9, 2026 | americanbankingnews.comBarricks gold output fell from 2 million ounces to 719000Barrick's gold production has plunged from 2 million ounces to just 719,000, leaving the world's second-largest miner running on fumes. Newmont's $15 billion purchase of Newcrest, the largest mining deal in history, still couldn't keep output growing, proof that majors must keep buying to survive. With record cash flows and shrinking mines, gold majors are positioned to launch a wave of acquisitions targeting the best junior assets.August 16 at 1:00 AM | Golden Portfolio (Ad)Quince Therapeutics, Inc. (NASDAQ:QNCX) Receives Average Rating of "Hold" from BrokeragesAugust 5, 2026 | americanbankingnews.comQuince TherapeuticsJuly 6, 2026 | fool.comQuince Therapeutics Stock Short Interest Report | NASDAQ:QNCX | BenzingaJuly 2, 2026 | benzinga.comQuince Therapeutics Appoints Recognized Leaders in Pulmonary Medicine to Scientific Advisory BoardJune 30, 2026 | globenewswire.comQuince Therapeutics, Inc. (QNCX) Shareholder/Analyst Call Prepared Remarks TranscriptJune 11, 2026 | seekingalpha.comSee More Headlines QNCX Stock Analysis - Frequently Asked Questions How have QNCX shares performed this year? Quince Therapeutics' stock was trading at $670.00 at the start of the year. Since then, QNCX shares have decreased by 94.9% and is now trading at $34.04. How were Quince Therapeutics' earnings last quarter? Quince Therapeutics, Inc. (NASDAQ:QNCX) announced its earnings results on Friday, August, 14th. The company reported ($12.31) EPS for the quarter, beating analysts' consensus estimates of ($28.02) by $15.71. When did Quince Therapeutics' stock split? Quince Therapeutics's stock reverse split on the morning of Tuesday, June 30th 2026.The 1-20 reverse split was announced on Friday, June 26th 2026. The number of shares owned by shareholders was adjusted after the market closes on Monday, June 29th 2026. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. When did Quince Therapeutics IPO? Quince Therapeutics (QNCX) raised $75 million in an initial public offering (IPO) on Thursday, May 9th 2019. The company issued 4,412,000 shares at a price of $16.00-$18.00 per share. Who are Quince Therapeutics' major shareholders? Top institutional shareholders of Quince Therapeutics include BlackRock Inc. (0.17%). Insiders that own company stock include David Lamond, Dirk Thye, Brendan Hannah and Charles S Ryan. View institutional ownership trends. How do I buy shares of Quince Therapeutics? Shares of QNCX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Quince Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Quince Therapeutics investors own include PayPal (PYPL), SoFi Technologies (SOFI), TherapeuticsMD (TXMD), Achilles Therapeutics (ACHL), Agile Therapeutics (AGRX) and Aytu BioPharma (AYTU). Company Calendar Last Earnings8/14/2026Today8/16/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2w+) 1-Year History Aug 25 Nov 25 Feb 26 May 26 Aug 26 For the last 2 weeks, QNCX's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:QNCX Previous SymbolNASDAQ:CRTX CIK1662774 Webwww.quincetx.com Phone(650) 910-5717FaxN/AEmployees60Year FoundedN/APrice Target and Rating Average Price Target for Quince Therapeutics$310.50 High Price Target$1,000.00 Low Price Target$80.00 Potential Upside/Downside+812.2%Consensus RatingHold Rating Score (0-4)2.27 Research Coverage11 Analysts Profitability EPS (Trailing Twelve Months)($156.71) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$83.98 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-67.99% Debt Debt-to-Equity RatioN/A Current Ratio2.92 Quick Ratio2.92 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($128.18) per share Price / Book-0.27Miscellaneous Outstanding Shares1,017,000Free Float945,000Market Cap$34.62 million OptionableOptionable Beta1.36 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NASDAQ:QNCX) was last updated on 8/16/2026 by MarketBeat.com Staff. From Our PartnersHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredYour 10X AI demo is starting…Keith Kaplan, the AI expert behind tools used by more than 100000 investors, built his models with an investme...TradeSmith | SponsoredWall Street is staring at the wrong AI tradeAnthropic just signed a 9.1 billion dollar, 20 year data center agreement covering 191 megawatts of capacity, ...The Oxford Club | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...Paradigm Press | SponsoredWhat is Trump’s decade-long obsession?No president has moved markets like Trump, adding and erasing trillions in value seemingly at will. Analyst...Brownstone Research | SponsoredA weekly dividend fund holding Nvidia and PalantirCrowdStrike, Palantir, Nvidia none of them pay a real dividend. But one fund holding the biggest AI names dist...Investors Alley | SponsoredElon admits defeatElon Musk just called Anthropic the clear leader in AI, admitting its Mythos model surpasses anything he's bui...Weiss Ratings | SponsoredThe dollar just brokeBloomberg research shows the U.S. dollar's share of global reserves has fallen to the lowest level this centur...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Quince Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Quince Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
